Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Compound was well-tolerated in patients, with no clinical or imaging evidence of vasogenic edema
Subscribe to our email newsletter
Pfizer has announced the results from two phase 1 safety studies. One of PF-04360365, a humanized anti-amyloid monoclonal antibody, and another of dimebon in combination with donepezil HCl tablets, in patients with Alzheimer’s disease.
A phase 1, single-dose, dose escalation study (0.1 to 10mg/kg) showed that the investigational compound PF-04360365 was well-tolerated in all patients. It showed no clinical or imaging evidence of vasogenic edema, and no new microhemorrhage or encephalitis reported in the ongoing follow-up period.
Steven Romano, vice president and head of Medical Affairs for Primary Care Business at Pfizer, said: “We are continuing to work with the global Alzheimer’s community to advance research in Alzheimer’s disease and currently have an investigational compound, dimebon (latrepirdine), in Phase 3 and two other compounds in Phase 2.”
The data was presented this week at the Alzheimer’s Association 2009 International Conference on Alzheimer’s Disease (ICAD) in Vienna, Austria.
Dimebon is being co-developed by Pfizer and Medivation, and is currently in phase 3 development stage.